Compare ALSN & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALSN | JAZZ |
|---|---|---|
| Founded | 1915 | 2003 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1B | 10.4B |
| IPO Year | 2012 | 2007 |
| Metric | ALSN | JAZZ |
|---|---|---|
| Price | $113.27 | $162.98 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 16 |
| Target Price | $103.71 | ★ $207.19 |
| AVG Volume (30 Days) | 808.7K | ★ 1.0M |
| Earning Date | 02-13-2026 | 02-24-2026 |
| Dividend Yield | ★ 0.95% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 8.15 | N/A |
| Revenue | $3,069,000,000.00 | ★ $4,157,832,999.00 |
| Revenue This Year | N/A | $6.05 |
| Revenue Next Year | N/A | $6.23 |
| P/E Ratio | $13.96 | ★ N/A |
| Revenue Growth | N/A | ★ 4.14 |
| 52 Week Low | $76.01 | $95.49 |
| 52 Week High | $117.07 | $182.99 |
| Indicator | ALSN | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 69.26 | 48.53 |
| Support Level | $112.17 | $162.24 |
| Resistance Level | $114.99 | $168.47 |
| Average True Range (ATR) | 2.25 | 4.02 |
| MACD | -0.09 | -0.39 |
| Stochastic Oscillator | 87.01 | 36.31 |
Allison Transmission is the largest manufacturer of fully automatic transmissions for medium- and heavy-duty commercial vehicles. Its automatic transmissions allow customers to achieve better fuel and operator efficiency than less expensive manual and automated manual transmissions. Allison serves several end markets, including on- and off-highway equipment and military vehicles. Its on-highway business commands approximately 60% global market share. The company's transmissions can be found in Class 4-8 trucks, buses, and a limited number of large passenger vehicles (heavy-duty pickup trucks and motorhomes). Allison also produces commercial hybrid propulsion systems and is developing fully electric powertrains.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.